Asymchem Laboratories (Tianjin) Co., Ltd.
6821.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.24B
Close$
$44.23
71.2% downside
Current Fair Value
71.2% downsideOvervalued by 71.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $59.24 Billion |
|---|---|
| Enterprise Value | $54.62 Billion |
| Dividend Yield | $1.50 (0.73%) |
| Earnings per Share | $3.19 |
| Beta | 0.06 |
| Outstanding Shares | 356,249,203 |
Return
| Return on Equity | 5.83% |
|---|---|
| Return on Assets | 4.97% |
| Return on Invested Capital | 6.90% |
Valuation & Multiples
| P/E Ratio | 61.36 |
|---|---|
| PEG | -235.93 |
| Price to Sales | 8.09 |
| Price to Book Ratio | 3.14 |
| Enterprise Value to Revenue | 7.75 |
| Enterprise Value to EBIT | 42.9 |
| Enterprise Value to Net Income | 52 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.26 B
Average shareholder expectationNext Earnings Call
Expected Date
October 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.43 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Asymchem Laboratories (Tianjin) Co., Ltd.
10,617 employees
CEO: Hao Hong Asymchem Laboratories (Tianjin) Co., Ltd. functions as a contract development and manufacturing organization (CDMO), offering its expertise to pharmaceutical and biotechnology companies both globally and within Mainland China. Their serv...